Ann: App 4E / Full Year Statutory Accounts, page-3

Anyone notice that Hepbarna is scheduled to begin phase 1 studies before TT-221 (AMD) even though its further behind in pre-clinical?

As per the financial review-

"As both HBV and HCV replicate in the liver, Benitec has designed Hepbarna to mimic the design elements of TT-034, which could expedite Hepbarna’s regulatory pathway"

Everyone knows this is the real "lead candidate". If TT-034 works this will have a very high chance of working as well. I believe this is what we will be making a deal for with Big Pharma. I don't know how most deals go but 50% Royalties for a couple hundred million dollars sounds good to me. Cash up!!!